The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
== Benefits over conventional filtration == A higher overall liquid removal rate is achieved by the prevention of filter cake formation Process feed remains in the form of a mobile slurry, suitable for further processing Solids content of the product slurry may be varied over a wide range It is possible to fractionate particles by size Tubular pinch effect
De Duve's work has contributed to the emerging consensus towards accepting the endosymbiotic theory; which idea proposes that organelles in eukaryotic cells originated as certain prokaryotic cells that came to live inside eukaryotic cells as endosymbionts. According to de Duve's version, eukaryotic cells with their structures and properties, including their ability to capture food by endocytosis and digest it intracellularly, developed first. Later, prokaryotic cells were incorporated to form more organelles. De Duve proposed that peroxisomes, which allowed cells to withstand the growing amounts of free molecular oxygen in the early-Earth atmosphere, may have been the first endosymbionts. Because peroxisomes have no DNA of their own, this proposal has much less evidence than similar claims for mitochondria and chloroplasts. His later years were mostly devoted to origin of life studies, which he admitted was still a speculative field (see thioester).
The People's Liberation Army (PLA) is the military wing of the Chinese Communist Party (CCP) and the primary armed forces of the People's Republic of China (PRC). It consists of four services—Ground Force, Navy, Air Force, and Rocket Force—and four arms—Aerospace Force, Cyberspace Force, Information Support Force, and Joint Logistics Support Force. It operates under the CCP's absolute control and is led by the Central Military Commission (CMC) with its chairman as commander-in-chief. Alongside the paramilitary People's Armed Police (PAP) and the Militia, the PLA forms the bulk of the country's armed forces. The PLA can trace its origins during the Republican era to the left-wing units of the National Revolutionary Army (NRA) of the Kuomintang (KMT), when they broke away in 1927 in an uprising against the nationalist government as the Chinese Red Army before being reintegrated into the NRA as units of New Fourth Army and Eighth Route Army during the Second Sino-Japanese War. The two NRA communist units were reconstituted as the PLA in 1947. Since 1949, the PLA has used nine different military strategies, which it calls "strategic guidelines". The most important came in 1956, 1980, and 1993. Politically, the PLA and the PAP have the largest delegation in the National People's Congress (NPC); the joint delegation currently has 281 deputies—over 9% of the total—all of whom are CCP members. The PLA is the armed wing of the CCP and controlled by the party, not by the state. The PLA's primary mission is the defense of the party and its interests.
=== Induced fit hypothesis === Daniel Koshland's theory of enzyme-substrate binding is that the active site and the binding portion of the substrate are not exactly complementary. The induced fit model is a development of the lock-and-key model and assumes that an active site is flexible and changes shape until the substrate is completely bound. This model is similar to a person wearing a glove: the glove changes shape to fit the hand. The enzyme initially has a conformation that attracts its substrate. Enzyme surface is flexible and only the correct catalyst can induce interaction leading to catalysis. Conformational changes may then occur as the substrate is bound. After the reaction products will move away from the enzyme and the active site returns to its initial shape. This hypothesis is supported by the observation that the entire protein domain could move several nanometers during catalysis. This movement of protein surface can create microenvironments that favour the catalysis.
Between 30 and 40 percent of people undergoing chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), a progressive, enduring, and often irreversible condition, causing pain, tingling, numbness and sensitivity to cold, beginning in the hands and feet and sometimes progressing to the arms and legs. Chemotherapy drugs associated with CIPN include thalidomide, epothilones, vinca alkaloids, taxanes, proteasome inhibitors, and the platinum-based drugs. Whether CIPN arises, and to what degree, is determined by the choice of drug, duration of use, the total amount consumed and whether the person already has peripheral neuropathy. Though the symptoms are mainly sensory, in some cases motor nerves and the autonomic nervous system are affected. CIPN often follows the first chemotherapy dose and increases in severity as treatment continues, but this progression usually levels off at completion of treatment. The platinum-based drugs are the exception; with these drugs, sensation may continue to deteriorate for several months after the end of treatment. Some CIPN appears to be irreversible. Pain can often be managed with drug or other treatment but the numbness is usually resistant to treatment.
Sources: en.wikipedia.org
== Chemoenzymatic strategies == There is no general biochemical solution for macrocyclization of a peptide chain. Isolated tyrocidine (Tyc) TE domains can be used to cyclize chemically derived peptidyl-thioester substrates, providing a powerful route to new cyclic compounds. In order for this macrocyclization to occur, the peptide chain must be activated at its C-terminus with an N-acetylcysteamine (SNAC) leaving group. An alanine scan through the 10 positions of tyrocidine shows that only the D-Phe and L-Orn are required for sufficient cyclization.
=== Pharmacokinetics === Suvomipic is used topically on the scalp instead of orally for potential safety and tolerability reasons. As an example, MPCs and pyruvate availability also prominently regulate stem cells and cellular growth in the intestines. The drug is said to be unstable in blood, which limits the risk of systemic absorption and side effects. It is said to have been engineered to be 1,000 times more effective at "penetrating" skin than blood. No suvomipic was detected in circulation with topical administration to the scalp in clinical studies.
== Medical uses == Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression. Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
== Connection and treatment of autism == Effective therapies to manage autism remain scarce. According to the exorphin theory of autism, an increase in the levels of exorphin is linked to symptoms of autism. Based on this concept, experiments have attempted to reduce the symptoms of autism by using large amounts of protease to break down exorphins before they are absorbed. Experiments have also attempted to enhance and utilize enzymes existing in the gut to break down exorphins in a similar fashion, since the production of exorphins within the gut is inevitable.
Sources: en.wikipedia.org
is the speed of light in vacuum. Typical metals that support surface plasmons are silver and gold, but metals such as copper, titanium or chromium have also been used. When using light to excite SP waves, there are two configurations which are well known. In the Otto configuration, the light illuminates the wall of a glass block, typically a prism, and is totally internally reflected. A thin metal film (for example gold) is positioned close enough to the prism wall so that an evanescent wave can interact with the plasma waves on the surface and hence excite the plasmons. In the Kretschmann configuration (also known as Kretschmann–Raether configuration), the metal film is evaporated onto the glass block. The light again illuminates the glass block, and an evanescent wave penetrates through the metal film. The plasmons are excited at the outer side of the film. This configuration is used in most practical applications.
=== Transcriptional dysregulation === CREB-binding protein (CBP), a transcriptional coregulator, is essential for cell function because as a coactivator at a significant number of promoters, it activates the transcription of genes for survival pathways. CBP contains an acetyltransferase domain to which HTT binds through its polyglutamine-containing domain. Autopsied brains of those who had Huntington's disease also have been found to have incredibly reduced amounts of CBP. In addition, when CBP is overexpressed, polyglutamine-induced death is diminished, further demonstrating that CBP plays an important role in Huntington's disease and neurons in general.
Cancer begins as cells that grow uncontrollably, usually as a result of an internal change or oncogenic mutations within the cell. Cancer develops and progresses as the microenvironment undergoes dynamic changes. The stromal reaction in cancer is similar to the stromal reaction induced by injury or wound repair: increased extracellular matrix (ECM) and growth factor production and secretion, which consequently cause growth of the tissue. In other words, the body reacts similarly to a cancer as it does to a wound, causing scar-like tissue to be built around the cancer. As such, the surrounding stroma plays a very important role in the progression of cancer. The interaction between cancer cells and surrounding tumor stroma is thus bidirectional, and the mutual cellular support allows for the progression of the malignancy.
Ecdysozoa () is a group of protostome animals, including Arthropoda (insects, chelicerates (including arachnids), crustaceans, and myriapods), Nematoda, and several smaller phyla. The grouping of these animal phyla into a single clade was first proposed by Eernisse et al. (1992) based on a phylogenetic analysis of 141 morphological characters of ultrastructural and embryological phenotypes. This clade, that is, a group consisting of a common ancestor and all its descendants, was formally named by Aguinaldo et al. in 1997, based mainly on phylogenetic trees constructed using 18S ribosomal RNA genes. A large study in 2008 by Dunn et al. strongly supported the monophyly of Ecdysozoa. The group Ecdysozoa is supported by many morphological characters, including growth by ecdysis, with moulting of the cuticle – without mitosis in the epidermis – under control of the prohormone ecdysone, and internal fertilization. The group was initially contested by a significant minority of biologists. Some argued for groupings based on more traditional taxonomic techniques, while others contested the interpretation of the molecular data.
In Buddhism, the Dharma Chakra is widely used to represent the Buddha's Dharma (Buddha's teaching and the universal moral order), Gautama Buddha himself and the walking of the path to enlightenment, since the time of Early Buddhism. The symbol is also sometimes connected to the Four Noble Truths, the Noble Eightfold Path and Dependent Origination. The pre-Buddhist dharmachakra (Pali: dhammacakka) is considered one of the ashtamangala (auspicious signs) in Hinduism and Buddhism and often used as a symbol of both faiths. It is one of the oldest known Indian symbols found in Indian art, appearing with the first surviving post-Indus Valley Civilisation Indian iconography in the time of the Buddhist king Ashoka. The Buddha is said to have set the "wheel of dharma" in motion when he delivered his first sermon, which is described in the Dhammacakkappavattana Sutta. This "turning of the wheel" signifies a great and revolutionary change with universal consequences, brought about by an exceptional human being. Buddhism adopted the wheel as a symbol from the Indian mythical idea of the ideal king, called a chakravartin ("wheel-turner", or "universal monarch"), who was said to possess several mythical objects, including the ratana cakka (the ideal wheel). The Mahā Sudassana Sutta of the Digha Nikaya describes this wheel as having a nave (nābhi), a thousand spokes (sahassārāni) and a felly (nemi), all of which are perfect in every respect.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.